Radioimmunoconjugates in acute leukemia treatment: The future is radiant

Bone Marrow Transplantation

Volumn 36, Issue 12, 2005, Pages 1021-1026

  Kotzerke, Joerg ^a   Bunjes, D ^b   Scheinberg, D A ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Conditioning; Leukemia; Radioimmunoconjugates; Radioimmunotherapy; Radioisotopes; Stem cell transplantation

Indexed keywords

ACTINIUM; ALEMTUZUMAB; ASTATINE 211; BISMUTH 213; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IODINE 131; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD33; MONOCLONAL ANTIBODY CD45; MONOCLONAL ANTIBODY CD66; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RHENIUM 188; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER MORTALITY; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; REVIEW; RISK REDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BETA RAYS; CELL ADHESION MOLECULES; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOCONJUGATES; LEUKEMIA; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOMETRY; RHENIUM; STEM CELL TRANSPLANTATION; YTTRIUM RADIOISOTOPES;

EID: 30544449271     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705182     Document Type: Review

References (38)

1. Appelbaum F. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Sem Oncol 1997; 24: 114-123.
2. Barrett A, Horowitz M, Ash R et al. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79: 3067-3070.
3. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens [see comments]. Blood 1990; 76: 1867-1871.
4. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991; 77: 1660-1665.
5. Corcoran M, Press O, Matthews D et al. The role of radioimmunotherapy in bone marrow transplantation. Curr Opin Haematol 1996; 3: 438-445.
6. Mulford DA, Jurcic JG. Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther 2004; 4: 95-105.
7. Griffiths GL, Goldenberg DM, Knapp Jr FF et al. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: Labeling and animal biodistribution studies. Cancer Res 1991; 51: 4594-4602.
8. 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med 2000; 41: 531-537.
9. Grossbard M, Press O, Appelbaum F et al. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
10. Burke JM, Caron PC, Papadopoulos EB et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32: 549-556.
11. Jurcic JG, Larson SM, Sgouros G et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233-1239.
12. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85: 1122-1131.
13. Bunjes D, Buchmann I, Duncker C et al. Rhenium 188-labeled anti-CD 66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study. Blood 2001; 98: 565-572.
14. Reske S, Bunjes D, Buchmann I et al. Targeted bone marrow irradiation in the conditioning of high-risk leukemia prior to stem cell transplantation. Eur J Nucl Med 2001; 28: 807-815.
15. Bordessoule D, Jones M, Gatter KC, Mason DY. Immunohistological patterns of myeloid antigens: Tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67. Br J Haematol 1993; 83: 370-383.
16. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control 2002; 9: 106-113.
17. Pagel JM, Matthews DC, Appelbaum FR et al. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant 2002; 29: 807-816.
18. Goldenberg DM, Gaffar SA, Bennett SJ et al. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981; 41: 4354-4360.
19. Appelbaum FR, Matthews DC, Eary JF et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829-833.
20. Scheinberg DA, Lovett D, Divgi CR et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478-490.
21. Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237-1247.
22. Vaidyanathan G, Zalutsky MR. Protein radiohalogenation: Observations on the design of N-succinimidyl ester acylation agents. Bioconjug Chem 1990; 1: 269-273.
23. Schubiger PA, Hasler PH, Novak Hofer I, Blauenstein P. Assessment of the binding properties of Granuloszint. Eur J Nucl Med 1989; 15: 605-608.
24. Seitz U, Neumaier B, Glatting G et al. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med 1999; 26: 1265-1273.
25. Siegel JA, Thomas SR, Stubbs JB et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40: 37S-61S.
26. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
27. Forster GJ, Engelbach MJ, Brockmann JJ et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: Comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 2001; 28: 1743-1750.
28. Friesen C, Leubatschofski A, Kotzerke J et al. Beta-irradiation used for systemic radiommunotherapy induces apotosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging 2003; 30: 1251-1261.
29. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leukemia Lymphoma 2002; 43: 2125-2131.
30. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
31. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
32. Jurcic J, Larson S, Sgouros G et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233-1239.
33. McDevitt M, Ma D, Lai L et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294: 1537-1540.
34. Ringhoffer M, Wiesneth M, Von Harsdorf S et al. CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: Clinical results in 102 patients. Br J Haematol 2004; 126: 527-535.
35. Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69-76.
36. Kottaridis P, Milligan D, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
37. Ringhoffer M, Blumstein N, Neumaier B et al. Re-188 or Y-90 labeled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phae I-II study. Br J Haematol 2005; 130: 604-613.
38. Pagel JM, Hedin N, Subbiah K et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003; 101: 2340-2348.